GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker’s application to expand the use of ...

London stocks were set to drop at the open on Friday amid escalating tensions in the Middle East, after Israel hit Iran’s ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...